De markt is gewoon niet groter dan het aantal patienten en er zijn al meerdere producten; kijk nu eens naar de huidige koers en wat Pharming kan krijgen. Is oud nieuws hoor en al eerder geroepen; heb niet voor niks op 20 en 30 cent verkocht. Is alleen maar opnieuw een waarschuwing en heb het al maanden mis -:)
There are currently five drugs that share the international Hereditary Angioedema (HAE) therapeutic market landscape. The US HAE market is crowded because there are only 6,000 patients with 4 products available.
Four Orphan Drugs
Dyax’s Kalbitor (Ecallantide) (US only) for acute HAE administered through subcutaneous injection
CSL Behring‘s Berinert (C1-esterase-inhibitor, human, pasteurized ) (US & EU) for acute HAE & administered through IV infusion
Shire’s Firazyr (Icatibant) (US & EU) for acute HAE & administered through subcutaneous injection
ViroPharma’s Cinryze (C1 esterase inhibitor (human)) (US & EU) for HAE prophylaxis & acute HAE (EU only) & administered through IV infusion.
One Non-Orphan Drug
Swedish Orphan Biovitrum’s (SOBI) Ruconest (recombinant human C1 inhibitor) (EU only) for HAE prophylaxis.
Until 2008, Berinert is the only therapy approved in Europe, while in the US there are no approved therapies. Since 2008, 5 HAE therapies are approved during 2008 – 2011, consisting of Cinryze, Firazyr, Berinert and Kalbitor in the US, and Cinryze, Firazyr and Ruconest in Europe. By 2019, according to Global Data, the following approvals are expected : Kalbitor (Europe), Rhucin (US), Firazyr (Japan), Kalbitor (Japan), and Cinryze (Japan). Global Data values the “global HAE therapeutics market at $113.8 million in 2011 with a forecast growth at a CAGR of 16.5 % to reach $385 million in 2019.”